PURETECH HEALTH PLC - ADR (PRTC) Stock Price, Quote, News and Overview
NASDAQ:PRTC - Nasdaq - US7462371060 - ADR - Currency: USD
PRTC Quote, Performance and Key Statistics
18.47
+0.12 (+0.65%)
The current stock price of PRTC is 18.47 USD. In the past month the price increased by 5.3%. In the past year, price decreased by -19.7%.
PRTC Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About PRTC
Company Profile
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 90 full-time employees. The company went IPO on 2015-06-19. The firm's R&D engine has resulted in the development of around 29 therapeutics and therapeutic candidates, including two that have received both United States Food and Drug Administration (FDA) clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. Its product candidates include LYT-100, LYT-200, SPT-300, SPT-310 and SPT-320. LYT-100 (deupirfenidone) is being developed internally by the Company for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is being developed for the treatment of hematological malignancies, such as acute myeloid leukemia and high-risk myelodysplastic syndromes, as well as locally advanced/metastatic solid tumors. SPT-300 is an oral prodrug of allopregnanolone, which is being advanced for the treatment of anxious depression.
Company Info
PURETECH HEALTH PLC - ADR
6 Tide Street, Suite 400
Boston MASSACHUSETTS 02210 US
CEO: Daphne Zohar
Employees: 90
Company Website: https://puretechhealth.com/
Investor Relations: https://investors.puretechhealth.com/
Phone: 16174822333
PURETECH HEALTH PLC - ADR / PRTC FAQ
What is the stock price of PURETECH HEALTH PLC - ADR today?
The current stock price of PRTC is 18.47 USD. The price increased by 0.65% in the last trading session.
What is the ticker symbol for PURETECH HEALTH PLC - ADR stock?
The exchange symbol of PURETECH HEALTH PLC - ADR is PRTC and it is listed on the Nasdaq exchange.
On which exchange is PRTC stock listed?
PRTC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PURETECH HEALTH PLC - ADR stock?
6 analysts have analysed PRTC and the average price target is 64 USD. This implies a price increase of 246.5% is expected in the next year compared to the current price of 18.47. Check the PURETECH HEALTH PLC - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PURETECH HEALTH PLC - ADR worth?
PURETECH HEALTH PLC - ADR (PRTC) has a market capitalization of 442.21M USD. This makes PRTC a Small Cap stock.
How many employees does PURETECH HEALTH PLC - ADR have?
PURETECH HEALTH PLC - ADR (PRTC) currently has 90 employees.
What are the support and resistance levels for PURETECH HEALTH PLC - ADR (PRTC) stock?
PURETECH HEALTH PLC - ADR (PRTC) has a support level at 17.52 and a resistance level at 18.7. Check the full technical report for a detailed analysis of PRTC support and resistance levels.
Should I buy PURETECH HEALTH PLC - ADR (PRTC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PRTC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PRTC, evaluating the profitability, health, valuation and growth aspects
- PURETECH HEALTH PLC - ADR (PRTC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PURETECH HEALTH PLC - ADR (PRTC) Sales and EPS estimates to see what analysts future expectations are.
- PURETECH HEALTH PLC - ADR (PRTC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PURETECH HEALTH PLC - ADR (PRTC) Insider and Institutional Ownership to learn about the owners and their transactions.
- PURETECH HEALTH PLC - ADR (PRTC) Stock Chart to make your own analysis
- PURETECH HEALTH PLC - ADR (PRTC) Latest news and press-releases to stay up to date.
Does PURETECH HEALTH PLC - ADR (PRTC) stock pay dividends?
PRTC does not pay a dividend.
When does PURETECH HEALTH PLC - ADR (PRTC) report earnings?
PURETECH HEALTH PLC - ADR (PRTC) will report earnings on 2025-04-23, after the market close.
What is the Price/Earnings (PE) ratio of PURETECH HEALTH PLC - ADR (PRTC)?
PURETECH HEALTH PLC - ADR (PRTC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.39).
What is the Short Interest ratio of PURETECH HEALTH PLC - ADR (PRTC) stock?
The outstanding short interest for PURETECH HEALTH PLC - ADR (PRTC) is 0.11% of its float. Check the ownership tab for more information on the PRTC short interest.
PRTC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to PRTC. When comparing the yearly performance of all stocks, PRTC is a bad performer in the overall market: 84.48% of all stocks are doing better.
PRTC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRTC. The financial health of PRTC is average, but there are quite some concerns on its profitability.
PRTC Financial Highlights
Over the last trailing twelve months PRTC reported a non-GAAP Earnings per Share(EPS) of -3.39. The EPS decreased by -80.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.22% | ||
| ROE | -26.11% | ||
| Debt/Equity | 0.05 |
PRTC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to PRTC. The Buy consensus is the average rating of analysts ratings from 6 analysts.